Kidney Disease Clinical Trial
Official title:
Interdialytic Kt/V Variability Measurement With Adimea (IVP STUDY)
Session-to-session variations in delivered Kt/V that may cause failure to achieve the
prescribed dialysis dose may be significant in regular clinical practice. To date, this is
not recognized due to monthly blood Kt/V measurements only. Suboptimal delivery of
prescribed dialysis dose may be caused by low effective treatment time, vascular access
dysfunction, hemodynamic stability, blood pump speed, membrane influences, lab value
variability or others which may vary from session to session. Patients close to recommended
target limits of dialysis dose may thus be "randomly" attributed to be adequately or
inadequately dialyzed. Therefore, in the literature, use of average Kt/V values is
recommended.
Adimea allows easy Kt/V determination in every session and thus documentation of the monthly
achieved Kt/V in patients who repeatedly miss Kt/V. Knowledge, therefore, of
session-to-session variability as well as knowledge of dialysis dose monitoring at every
dialysis may enhance and secure delivery of adequate dialysis.
The main objective is the estimation of the pooled within-patient SDs (standard deviation)
for single treatment Adimea and of urea kinetic modeling (UKM)/ blood spKt/V. Failure of
Kt/V>1.2 delivery as well as its potential causes will be assessed. spKt/V target
achievement is assessed by monitoring dose by Adimea at every dialysis. This shall
demonstrate that session-to-session variability can be decreased with usage of Adimea.
n/a
Observational Model: Case-Only, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02369354 -
Transplant Social Worker Support for Live Kidney Donation in African Americans
|
N/A | |
| Not yet recruiting |
NCT02225782 -
Trial to Compare 1.0 Versus 2.0 mg Alteplase (tPA) Dosing in Restoring Hemodialysis Catheter Function
|
Phase 4 | |
| Completed |
NCT00499187 -
Fanconi Syndrome Due to ARVs in HIV-Infected Persons
|
Phase 4 | |
| Completed |
NCT00379899 -
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
|
Phase 4 | |
| Withdrawn |
NCT00585429 -
Evaluation of Kidney Disease in Liver Transplant Recipients
|
N/A | |
| Completed |
NCT00183248 -
Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT00001835 -
Oxaliplatin in Cancer Patients With Impaired Kidney Function
|
Phase 1 | |
| Completed |
NCT01331941 -
A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function
|
Phase 1 | |
| Terminated |
NCT00436748 -
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
|
Phase 3 | |
| Completed |
NCT01467466 -
Prevention of Serious Adverse Events Following Angiography
|
Phase 3 | |
| Completed |
NCT01235936 -
Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia
|
Phase 2 | |
| Completed |
NCT01974999 -
A Retrospective Multicenter Study to Determine 5-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-01 Study
|
||
| Recruiting |
NCT01240564 -
The Nephrotic Syndrome Study Network (NEPTUNE)
|
N/A | |
| Active, not recruiting |
NCT01228903 -
Uric Acid and the Endothelium is CKD
|
N/A | |
| Completed |
NCT00734357 -
Comparative Investigation of Intravenously Administered Omnipaque and Isovue: Effects on Serum Creatinine Concentration in Outpatients
|
N/A | |
| Completed |
NCT00781417 -
Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease
|
N/A | |
| Completed |
NCT00096915 -
Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis
|
Phase 3 | |
| Completed |
NCT00094484 -
Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis
|
Phase 3 | |
| Completed |
NCT00093977 -
Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease
|
Phase 3 | |
| Completed |
NCT00185159 -
Olmesartan Medoxomil in Diabetes Mellitus
|
Phase 3 |